UC Berkeley Awards $200,000 Venture Grant to HypO2Regen Therapeutics with Future Investment Option

UC Berkeley has awarded a $200,000 venture grant to HypO2Regen Therapeutics, a company focused on advancements in life sciences. The funding includes $100,000 from the university’s Life Sciences Entrepreneurship Center and an additional $100,000 from Berkeley SkyDeck. Furthermore, Berkeley SkyDeck retains the option to invest another $100,000 in the future.

The grant aims to support HypO2Regen Therapeutics in its efforts to develop innovative solutions within the life sciences sector. This dual-source funding reflects UC Berkeley’s commitment to fostering entrepreneurship and innovation through its programs. The involvement of both the Life Sciences Entrepreneurship Center and Berkeley SkyDeck highlights their collaborative approach in providing financial backing for emerging ventures.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 3, 2025

Related posts:

Biosimilar Competition to Impact 80% of Biologics by 2029, FDA Reduces Approval Times by 50% DrugPatentWatch: 505(b)(2) Applications and Patent Extensions Offer Strategies for Post-ANDA Market Exclusivity. UCLA Study Finds SSRIs Enhance T Cell Activity and Reduce Tumor Growth in Preclinical Cancer Models FDA Commissioner Launches Initiative to Engage Stakeholders Through Meetings and Site Visits

Author

Mark Chiang